Biologics in systemic lupus erythematosus: Current options and future perspectives

British Journal of Hospital Medicine

Volumn 75, Issue 8, 2014, Pages 440-447

  Md Yusof, Md Yuzaiful ^a   Vital, Edward M ^b,c   Emery, Paul ^b,c  

^a Dept of Rheumatology ^*  (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; IMMUNOLOGIC FACTOR;

HUMAN; MOLECULARLY TARGETED THERAPY; PATHOLOGY; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS;

BIOLOGICAL PRODUCTS; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MOLECULAR TARGETED THERAPY;

EID: 84908243498     PISSN: 17508460     EISSN: 17597390     Source Type: Journal    
DOI: 10.12968/hmed.2014.75.8.440     Document Type: Conference Paper

References (32)

1. AstraZeneca (2014) AstraZeneca announces MedImmune's mavrilimumab and sifalimumab both met primary endpoints in Phase IIb studies. http://www.astrazeneca.com/Media/Press-releases/Article/20140512-astrazeneca-announces-medimmunes-mavrilimumab-sifalimumab-met-primary-endpoints-Phase-IIb-studies (accessed 26 July 2014).
2. Boross P, Leusen JHW (2012) Mechanisms of action of CD20 antibodies. Am J Cancer Res 2: 676-90.
3. Cervera R, Khamashta MA, Font J et al, the European Working Party on Systemic Lupus Erythematosus (2003) Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1, 000 patients. Medicine (Baltimore) 82: 299-308.
4. Dall'era MC, Cardarelli PM, Preston BT, Witte A, Davis JC Jr (2005) Type I interferon correlates with serological and clinical manifestations of SLE. Ann Rheum Dis 64: 1692-7.
5. Díaz-Lagares C, Croca S, Sangle S et al, and the UK-BIOGEAS Registry (2012) Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts. Autoimmun Rev 11: 357-64 (doi: 10.1016/j.autrev.2011.10.009).
6. Furie R, Merrill J, Wallace D et al (2010) Four year experience of belimumab, a BLyS-specific inhibitor, in systemic lupus erythematosus (SLE): LBSL02/99 Study. J Clin Rheumatol 16(3): S58-S59.
7. Furie R, Petri M, Zamani O et al, and the BLISS-76 Study Group (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63: 3918-30 (doi: 10.1002/art.30613).
8. Furie R, Nicholls K, Cheng TT et al (2014a) Efficacy and safety of abatacept in lupus nephritis: A twelve-month, randomized, double-blind study. Arthritis Rheumatol 66: 379-89 (doi: 10.1002/art.38260).
9. Furie RA, Leon G, Thomas M et al, for the PEARL-SC Study (2014b) A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. Ann Rheum Dis (doi: 10.1136/annrheumdis-2013-205144).
10. Furie RA, Petri M, Gordon C et al (2014c) Correlation of laboratory and clinical parameters with British Isles Lupus Assessment Group reponse in an open-label extension tudy of epratuzumab in systemic lupus erythematosus. Ann Rheum Dis 73 (Suppl2) (doi: 10.1136/annrheumdis-2014-eular.1854).
11. Ginzler EM, Wax S, Rajeswaran A, Copt S, Hillson J, Ramos E, Singer NG (2012) Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther 14: R33 (doi: 10.1186/ar3738).
12. Ginzler EM, Wallace DJ, Merrill JT et al, the LBSL02/99 Study Group (2014) Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol 41: 300-9 (doi: 10.3899/jrheum.121368).
13. Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D (2014) Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis (doi: 10.1136/annrheumdis-2013-205067).
14. Kalunian K, Merrill JT, Maciuca R et al (2012) Efficacy and safety of rontalizumab (anti-interferon alpha) in SLE subjects with restricted immunosuppressant use: results of a randomized, double-blind, placebo controlled Phase 2 study. Arthritis Rheum 64: S1111- S1111.
15. La Cava A (2009) Lupus and T cells. Lupus 18: 196-201 (doi: 10.1177/0961203308098191).
16. Lim SH, Vaughan AT, Ashton-Key M et al (2011) Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. Blood 118: 2530-40 (doi: 10.1182/blood-2011- 01-330357).
17. Manzi S, Sánchez-Guerrero J, Merrill JT et al, the BLISS-52 and BLISS-76 Study Groups (2012) Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 71: 1833-8 (doi: 10.1136/annrheumdis-2011-200831).
18. Md Yusof MY, Vital EM, Emery P (2013) B-cell-targeted therapies in systemic lupus erythematosus and ANCA-associated vasculitis: current progress. Expert Rev Clin Immunol 9: 761-72 (doi: 10.1586/1744666X.2013.816479).
19. Merrill JT, Burgos-Vargas R, Westhovens R et al (2010a) The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 62: 3077-87 (doi: 10.1002/art.27601).
20. Merrill JT, Neuwelt CM, Wallace DJ et al (2010b) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62: 222-33 (doi: 10.1002/art.27233).
21. Mysler EF, Spindler AJ, Guzman R et al (2013) Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum 65: 2368-79 (doi: 10.1002/art.38037).
22. Navarra SV, Guzmán RM, Gallacher AE et al, the BLISS-52 Study Group (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial. Lancet 377: 721-31 (doi: 10.1016/S0140- 6736(10)61354-2).
23. Ramos-Casals M, Soto M, Cuadrado M, Khamashta M (2009) Rituximab in systemic lupus erythematosus A systematic review of off-label use in 188 cases. Lupus 18: 767-76 (doi: 10.1177/0961203309106174).
24. Rovin BH, Furie R, Latinis K et al, the LUNAR Investigator Group (2012) Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64: 1215-26 (doi: 10.1002/art.34359).
25. van Vollenhoven RF, Petri MA, Cervera R et al (2012) Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 71: 1343-9 (doi: 10.1136/annrheumdis-2011-200937).
26. van Vollenhoven R, Aranow C, Rovin B, Wagner C, Zhou B, Gordon R, Hsu B (2014a) A phase 2, multicenter, randomized, double-blind, placebo-controlled, proof-of-concept study to evaluate the efficacy and safety of sirukumab in patients with active lupus nephritis. Ann Rheum Dis 73 (Suppl2) (doi: 10/1136/annrheumdis- 2014-eular.3974).
27. van Vollenhoven RF, Mosca M, Bertsias G et al (2014b) Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 73: 958-67 (doi: 10.1136/annrheumdis-2013-205139).
28. Vital EM, Emery P (2006) Abatacept in the treatment of rheumatoid arthritis. Ther Clin Risk Manag 2: 365-75.
29. Vital EM, Kay J, Emery P (2013) Rituximab biosimilars. Expert Opin Biol Ther 13: 1049-62 (doi: 10.1517/14712598.2013.787064).
30. Wallace DJ, Stohl W, Furie RA et al (2009) A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 61: 1168-78 (doi: 10.1002/art.24699).
31. Wallace DJ, Kalunian K, Petri MA et al (2014) Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. Ann Rheum Dis 73: 183-90 (doi: 10.1136/annrheumdis-2012-202760).
32. Wofsy D, Hillson JL, Diamond B (2012) Abatacept for lupus nephritis: Alternative definitions of complete response support conflicting conclusions. Arthritis Rheum 64: 3660-5 (doi: 10.1002/art.34624).